CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash Flows From Operating Activities:
Net loss	$ (61,057)	$ (42,145)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	67	57
Amortization of deferred financing costs	2,516
Stock-based compensation expense	7,794	2,264
Accretion of discount/premium on available for sale securities	(87)	28
Change in fair value of derivative instruments-warrants	1,810	(979)
Changes in operating assets and liabilities:
Security deposit	(56)	(69)
Accounts payable and accrued expenses	(1,294)	2,421
Prepaid expenses and other current assets	1,549	(1,086)
Accrued interest expense on Senior Convertible Debentures	(277)
Total Adjustments	12,022	2,636
Net Cash used in Operating Activities	(49,035)	(39,509)
Cash Flows From Investing Activities:
Net purchases of available-for-sale securities	(50,000)
Additions to property and equipment	(8)	(57)
Repayment on ContraVir loan receivable		455
Net Cash (used in) / provided by Investing Activities	(50,008)	398
Cash Flows From Financing Activities:
Proceeds of sale of common stock	14,672	22,795
Proceeds of sale of common stock - ContraVir		3,224
Fees and expenses - sale of common stock	(404)	(644)
Proceeds from exercise of stock options		36
Distribution associated with ContraVir Spinoff		(3,230)
Net Cash provided by Financing Activities	14,268	22,181
Net decrease in cash and cash equivalents	(84,775)	(16,930)
Cash and cash equivalents at beginning of period	146,470	18,130
Cash and cash equivalents at end of period	61,695	1,200
Supplementary disclosure of cash flow information:
Cash paid for interest on Senior Convertible Debentures	7,416
Cash paid for taxes	224	30
Supplementary disclosure of non-cash investing and financing activities:
Distribution of net assets of ContraVir		$ 84
Conversion of Senior Convertible Debentures to Synergy Common Stock	$ 22,213